As we celebrate the Fourth of July, we take a moment to reflect on the significance of the day when the United States laid down its foundation on the principles of freedom, democracy, and the pursuit of happiness. Wishing everyone a joyful and safe celebration! #IndependenceDay2024 #LatigoBio #Innovation #Healthcare #July4th
Latigo Biotherapeutics, Inc.
Biotechnology Research
Thousand Oaks, CA 5,067 followers
Uniquely poised to disrupt pain therapy.
About us
Latigo Biotherapeutics Inc., headquartered in Thousand Oaks, CA, is a privately held clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target the fundamental mechanism of pain transduction. The company’s proprietary, in-house technology generates novel drugs against targets validated by human genetics using the most advanced artificial intelligence, machine learning, structure-based, and knowledge-based design techniques to optimize potency and selectivity. The company is backed by top-tier investors, including Westlake Village BioPartners, 5AM Ventures, Foresite Capital, and Corner Ventures.
- Website
-
www.latigobio.com
External link for Latigo Biotherapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Thousand Oaks, CA
- Type
- Privately Held
Locations
-
Primary
Get directions
Thousand Oaks, CA, US
Employees at Latigo Biotherapeutics, Inc.
Updates
-
As we approach the middle of a momentous year, following the launch of Latigo Bio, we're taking a pause to reflect and recharge. In recognition of Independence Day and the efforts of our dedicated team, Latigo Bio will be closed for the week of July 4th. This break is our way of saying thank you to our team, providing everyone with the opportunity to spend quality time with family and friends, and to enjoy a well-deserved rest. #LatigoBio #July4th2024 #WorkLifeBalance #CompanyShutdown
-
-
Today, Juneteenth, marks the end of slavery and the beginning of a journey toward equality and justice in the United States. At Latigo Biotherapeutics, we honor this day by reflecting on our shared history, celebrating the progress made, and committing to fostering a future where everyone has the opportunity to thrive. https://lnkd.in/g9GmYbWQ #Juneteenth #Equalityofopportunity #Diversity #LatigoBiotherapeutics
Why is Juneteenth Important?
nmaahc.si.edu
-
It’s not just about science — it's also about the people who make Latigo a dynamic and fulfilling place to work. At our Staff Spring Event we got a chance to get to know each other a little better and have some fun! #StaffSocial #BioTech #NonOpioid
-
-
We are excited to share that Victor Castro has been promoted to Research Associate II at Latigo Bio! Victor has consistently demonstrated exceptional dedication, expertise, and passion in his work, making significant contributions to our research endeavors. His commitment to excellence and unwavering drive embody the spirit of innovation that defines Latigo Bio. #Promotion #Research #Biotechnology #CareerGrowth #LatigoBio #Congratulations
-
-
Welcome Kevin Martin to the team here at Latigo Bio! #NonOpioid #BioTech #NewHires
-
-
In honor of Women’s History Month, we asked some of our leaders what they think is the most exciting thing about working in biotech. #BioTech #AutoImmuneDiseases #WomensHistoryMonth Shalvi Patel
-
-
Welcome Robin Valtchev to the team here at Latigo Bio! #NonOpioid #BioTech #NewHires
-
-
In honor of Women’s History Month, we asked some of our leaders what they think is the most exciting thing about working in biotech. #BioTech #AutoImmuneDiseases #WomensHistoryMonth Holly Carlisle
-
-
We are excited to share that the American Society for Pharmacology and Experimental Therapeutics - ASPET published our paper in Molecular Pharmacology entitled “Pharmacologic Characterization of LTGO-33, a Selective Small Molecule Inhibitor of the Voltage-Gated Sodium Channel NaV1.8 with a Unique Mechanism of Action.” You can read it here: https://lnkd.in/gJ8MjAj5 #nonopioid #pain #molecularpharmacology #biotech
Pharmacologic Characterization of LTGO-33, a Selective Small Molecule Inhibitor of the Voltage-Gated Sodium Channel NaV1.8 with a Unique Mechanism of Action
molpharm.aspetjournals.org